Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort

Published:2010-08-30 Issue:9 Volume:32 Page:1129-1134
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

Waugh A. W. G.,Garg S.,Matic K.,Gramlich L.,Wong C.,Sadowski D. C.,Millan M.,Bailey R.,Todoruk D.,Cherry R.,Teshima C. W.,Dieleman L.,Fedorak R. N.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2010.04446.x/fullpdf

Reference21 articles.

1. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

2. Infliximab for the treatment of fistulas in patients with Crohn’s disease;Present;N Engl J Med,1999

3. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease;Rutgeerts;Gastroenterology,2004

4. Infliximab maintenance therapy for fistulizing Crohn’s disease;Sands;N Engl J Med,2004

5. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group;Targan;N Engl J Med,1997

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission;Clinical and Experimental Medicine;2023-01-12

2. Miscellaneous Questions About IBD;Managing Complex Cases in Gastroenterology;2023

3. Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease—A Review of the Evidence;Frontiers in Pediatrics;2021-09-21

4. Editorial: withdrawal of anti‐TNFalpha—are we ready for biological therapy cycling? Authors' reply;Alimentary Pharmacology & Therapeutics;2021-06-09

5. Clinical outcome after anti‐tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long‐term study;Alimentary Pharmacology & Therapeutics;2021-05-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3